Antihypertensive Use and the Risk of Cataract in Patients with Hypertension: A Nationwide Case-control Study

• Published in: Ophthalmic epidemiology 2023-09, Vol.ahead-of-print (ahead-of-print), p.1-10
• Main Authors: Yang, Hye Lim, Byun, Seong Jun, Park, Sewon, Lee, Sung Hoon, Park, Sang Jun, Jung, Sun-Young
• Format: Article
• Language: English
• Subjects: ACE inhibitor; angiotensin II receptor blocker; antihypertensives; beta-blocker; calcium channel blocker; case-control study; Cataract; thiazide diuretic
• ISSN: 0928-6586; 1744-5086
• DOI: 10.1080/09286586.2022.2145612

This study aims to investigate the association between antihypertensive use and the risk of cataract in a matched case-control study. We analysed the Korean National Health Insurance Service-Health Screening Cohort database from 2002 to 2013. We defined 'cases' as patients prescribed antihypertensives and underwent their first eye cataract surgery between 2010 and 2013. 'Controls' were patients prescribed antihypertensives and no history of cataract surgery or diagnosis between 2002 and 2013. Four controls were matched to each case by several variables. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated for cataract risk using a conditional logistic regression model after adjustment. The analyses comprised 12,166 cases and 48,664 controls. The adjusted ORs for cataracts were 1.18 (95% CI: 1.12-1.24) in thiazide diuretics, 1.12 (95% CI: 1.07-1.18) in beta-blockers, 0.94 (95% CI: 0.90-1.00) in calcium channel blockers, 1.22 (95% CI: 1.14-1.30) in angiotensin-converting enzyme (ACE) inhibitors, and 0.97 (95% CI: 0.91-1.03) in angiotensin II receptor blockers compared to 'non-use' of each antihypertensive. In a nationwide case-control study, the use of thiazide diuretics, beta-blockers, or ACE inhibitors do not represent minimal clinical important difference in the risk of cataract and the use of calcium channel blockers or angiotensin II receptor blockers is not associated with an increased risk of cataracts compared to non-use of each antihypertensive. Given the benefits of treating hypertension, such as the reduction in further complications, we suggest there is no need to change current clinical practice for antihypertensives.